An interventional study of Remotely Supervised Cardiac Telerehabilitation and Usual Care and General Exercise Guidance in Atrial Fibrillation (AF), sponsored by Hande Cörüt. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Hande Cörüt · Not applicable, Interventional, and Treatment
Among 55 studies in Atrial Fibrillation with a site in Turkey — 8 open to participants now, 9 under way, 2 of them phase 3. Atrial Fibrillation · Turkey.
Among the 55 studies in Atrial Fibrillation with a site in Turkey, this one is the 30th largest by planned enrollment of the 30 interventional ones, is one of 4 that started in 2026, is one of 10 with no phase, and was the 53rd registered.
4,009 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
This study's planned enrollment of 28 is below the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →8 of the 55 studies in Atrial Fibrillation with a site in Turkey are open now, in 12 countries. Each count lists the studies.
Of the 612 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 50 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →55 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2026.
Median enrollment 1,314 across the 30 interventional studies, 400 across the 25 observational. Of the 40 that completed or were terminated, 15 (38%) have results posted.
20 of 55 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Hande Cörüt as lead sponsor.
Hande Cörüt has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
4 of the studies in Atrial Fibrillation with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07242326Kotyora Family Medicine Health Management and Education AssociationSNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye) | 2026-12-30 |
| NCT07877116Hüseyin Ulaş PinarSevoflurane Versus Propofol Anesthesia in Intracardiac Echocardiography-Guided Atrial Fibrillation Ablation | 2027-04 |
| NCT07808307Hande CörütTele-Rehabilitation After Catheter Ablation in Patients With Atrial Fibrillation | 2027-06 |
Among the 55 studies in Atrial Fibrillation with a site in Turkey, from their registry updates:
This study aims to investigate the effects of remotely supervised cardiac telerehabilitation in patients with atrial fibrillation who have undergone catheter ablation. Participants will be randomly assigned to a cardiac telerehabilitation group or a control group. The telerehabilitation group will receive a 12-week remotely supervised exercise program in addition to standard care, consisting of aerobic, strengthening, and stretching exercises. The control group will receive standard care and general exercise guidance without an individualized exercise program. Functional exercise capacity, muscle strength, arterial stiffness, heart rate variability, quality of life, physical activity, balance, cognitive function, anxiety and depression, and atrial fibrillation recurrence will be evaluated.
This is a single-blind, randomized controlled study involving patients with atrial fibrillation who have undergone catheter ablation. Participants meeting the eligibility criteria will be informed about the study and will provide written informed consent before participation.
Participants will be randomly allocated to either a remotely supervised cardiac telerehabilitation group or a control group. The cardiac telerehabilitation group will receive standard care plus a 12-week remotely supervised exercise program consisting of aerobic, strengthening, and stretching exercises. The program will be performed three days per week for a total of 36 sessions, with each session lasting approximately 45-60 minutes.
Aerobic exercise will initially be performed at moderate intensity, corresponding to 40-60% of heart rate reserve according to the Karvonen method and a perceived exertion of 4-6 on the Modified Borg Scale. Exercise intensity and duration will be progressively increased according to individual tolerance. Strengthening exercises will be performed using elastic resistance bands, with exercise intensity monitored using the Modified Borg Scale.
Exercise sessions will be conducted remotely by a physiotherapist using synchronous video-conferencing platforms or applications. Participants will use a Polar H10 chest heart rate sensor and a sports watch during exercise sessions. Exercise data will be uploaded to the PolarBeat platform and monitored remotely by the physiotherapist.
The control group will receive standard care and general information regarding the benefits of exercise and appropriate physical activity recommendations. Participants in the control group will be encouraged to achieve 150 minutes of moderate physical activity per week but will not receive an individualized exercise training program.
Assessments will include functional exercise capacity, muscle strength, handgrip strength, arterial stiffness, heart rate variability, anxiety and depression, atrial fibrillation-specific quality of life, physical activity, balance and fall risk, cognitive function, and atrial fibrillation recurrence. Adherence to the telerehabilitation program will also be recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive standard care plus a 12-week remotely supervised cardiac telerehabilitation exercise program consisting of aerobic, strengthening, and stretching exercises. The program will be performed three days per week for a total of 36 sessions, with each session lasting approximately 45-60 minutes.
Behavioral: Remotely Supervised Cardiac Telerehabilitation
Participants in this group will receive standard care and general exercise guidance. They will be encouraged to achieve 150 minutes of moderate physical activity per week but will not receive an individualized exercise training program.
Other: Usual Care and General Exercise Guidance
A 12-week remotely supervised cardiac telerehabilitation exercise program consisting of aerobic, strengthening, and stretching exercises. Participants will exercise three days per week for a total of 36 sessions, with each session lasting approximately 45-60 minutes. Exercise intensity will be individually prescribed and progressed according to participant tolerance.
Participants will receive standard care and general exercise guidance. They will be encouraged to achieve 150 minutes of moderate physical activity per week but will not receive an individualized exercise training program.
6 Minute Walk Test (6MWT) Distance
Distance walked during the 6-minute walk test, measured in meters, as an indicator of functional exercise capacity.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Muscle Strength
Maximum isometric muscle strength will be assessed using a hand-held dynamometer. Bilateral knee extension, shoulder flexion, shoulder abduction, elbow flexion, and elbow extension strength will be measured; the best value will be recorded in kilograms.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Handgrip Strength
Handgrip strength will be assessed using a Jamar hand dynamometer. Measurements will be performed three times for each hand at 5-second intervals, and the best value will be recorded in kilograms.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Arterial Stiffness-Carotid-Femoral Pulse Wave Velocity (cfPWV)
Carotid-Femoral Pulse Wave Velocity (cfPWV)
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Arterial Stiffness-Augmentation Index (AIx)
Augmentation Index (AIx) will be assessed noninvasively using the SphygmoCor XCEL device and reported as a percentage (%).
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability-SDNN
SDNN(ms) will be assessed using a Polar H10 heart rate sensor and Kubios HRV software from a 3-minute resting recording obtained with the participant in the supine position.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability - RMSSD
RMSSD(ms) will be assessed using a Polar H10 heart rate sensor and Kubios HRV software from a 3-minute resting recording obtained with the participant in the supine position.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability - Low-Frequency Power (LF)
Low-frequency (LF) power(ms²) will be assessed using a Polar H10 heart rate sensor and Kubios HRV software from a 3-minute resting recording obtained with the participant in the supine position.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability - High-Frequency Power (HF)
High-frequency (HF) power(ms²) will be assessed using a Polar H10 heart rate sensor and Kubios HRV software from a 3-minute resting recording obtained with the participant in the supine position.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability - LF/HF Ratio
The LF/HF ratio will be calculated using Kubios HRV software from a 3-minute resting recording obtained with the participant in the supine position.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Atrial Fibrillation-Specific Quality of Life
The Atrial Fibrillation Effect on Quality-of-Life Questionnaire (AFEQT) will be used to assess atrial fibrillation-specific health-related quality of life. The total score ranges from 0 to 100, with higher scores indicating better health-related quality of life.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Physical Activity Level
Physical activity level will be objectively assessed using a pedometer. Participants will wear the sensor during all waking hours, except during showering and swimming, for 7 consecutive days. Daily step counts and sensor wearing times will be recorded in an activity diary. Physical activity will be assessed during the first 7 days after baseline assessment and during the final 7 days following completion of the 12-week intervention.
Time frame: During the first 7 days after baseline assessment (1 week after catheter ablation) and during the final 7 days after completion of the 12-week intervention
HADS-Anxiety
The anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A) will be used to assess anxiety symptoms. The score ranges from 0 to 21, with higher scores indicating greater anxiety symptom severity.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
HADS - Depression
The depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) will be used to assess depressive symptoms. The score ranges from 0 to 21, with higher scores indicating greater depressive symptom severity
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Cognitive Function
Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The MoCA evaluates attention and concentration, executive functions, memory, language, visuospatial skills, abstraction, calculation, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive function.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Atrial Fibrillation Recurrence
Atrial fibrillation recurrence will be assessed by a cardiologist using 12-lead electrocardiography and 24-hour Holter monitoring. Atrial fibrillation recurrence will be defined as documented atrial fibrillation lasting more than 30 seconds.
Time frame: Throughout the 12-week intervention period, when clinically indicated
Telerehabilitation Program Adherence
Adherence to the telerehabilitation program will be calculated as the percentage of completed exercise sessions out of the 36 prescribed sessions. Participants will be categorized according to session attendance as adherent (\>80%), partially adherent (20%-80%), or non-adherent (\<20%).
Time frame: Throughout the 12-week intervention period
M-CTSIB - Sway Index, Eyes Open on Firm Surface
Sway Index will be assessed during the eyes-open condition on a firm surface using the Modified Clinical Test of Sensory Interaction on Balance (M-CTSIB) performed on the Biodex Balance System. Higher Sway Index values indicate greater postural sway and poorer postural stability.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
M-CTSIB - Sway Index, Eyes Closed on Firm Surface
Sway Index will be assessed during the eyes-closed condition on a firm surface using the Modified Clinical Test of Sensory Interaction on Balance (M-CTSIB) performed on the Biodex Balance System. Higher Sway Index values indicate greater postural sway and poorer postural stability.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
M-CTSIB - Sway Index, Eyes Open on Foam Surface
Sway Index will be assessed during the eyes-open condition on a foam surface using the Modified Clinical Test of Sensory Interaction on Balance (M-CTSIB) performed on the Biodex Balance System. Higher Sway Index values indicate greater postural sway and poorer postural stability.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
M-CTSIB - Sway Index, Eyes Closed on Foam Surface
Sway Index will be assessed during the eyes-closed condition on a foam surface using the Modified Clinical Test of Sensory Interaction on Balance (M-CTSIB) performed on the Biodex Balance System. Higher Sway Index values indicate greater postural sway and poorer postural stability.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Postural Stability - Overall Stability Index
Overall Stability Index will be assessed using the Postural Stability Test performed on the Biodex Balance System. Higher values indicate greater postural sway and poorer postural stability.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Postural Stability - Anterior/Posterior Stability Index
Anterior/Posterior Stability Index will be assessed using the Postural Stability Test performed on the Biodex Balance System. Higher values indicate greater anterior-posterior postural sway and poorer postural stability.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Postural Stability - Medial/Lateral Stability Index
Medial/Lateral Stability Index will be assessed using the Postural Stability Test performed on the Biodex Balance System. Higher values indicate greater medial-lateral postural sway and poorer postural stability.
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Plan to share: Undecided
Start is estimated for Sep 2026; primary completion for Jun 2027, 9 months later.
Of 796 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 9 months is below that.
Counting every sponsor, half of 1,051 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.